» Articles » PMID: 12927521

Specificity of Antibodies Directed Against the Cytolethal Distending Toxin of Haemophilus Ducreyi in Patients with Chancroid

Overview
Journal Microb Pathog
Date 2003 Aug 21
PMID 12927521
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Antibodies specific for the cytolethal-distending toxin of Haemophilus ducreyi (HdCDT) complex and for the CdtA, CdtB, and CdtC components were measured by ELISA in the sera of 50 patients with culture and/or PCR proven chancroid, 42 patients with periodontitis, 50 blood donors from Tanzania, 50 blood donors from Sweden. In addition, the biological activity e.g. neutralization capacity of the sera were tested. Our results demonstrate that majority of chancroid patients and healthy individuals had detectable levels of serum antibodies to HdCDT complex and to separate toxin components. However, high levels (> or =100 units) of antibodies to HdCDT complex were significantly more prevalent in the sera of patients with both chancroid and periodontitis than in the sera of the corresponding controls (P=0.001 and P=0.04, respectively). In the sera of the 50 patients with chancroid, antibodies to CdtA, CdtB, and CdtC were detected in 50, 35, and 34 individuals, respectively. Antibodies to CdtC, being less frequently detected than the antibodies to other components, show a good correlation with the neutralizing capacity of sera. High levels of neutralizing antibodies (> or =160) were detected in only 22 and 2% of the patients with chancroid and periodontitis, respectively. The data suggest that the low levels of anti-HdCDT antibodies, which include neutralizing antibodies, may contribute to limited protection in chancroid and since anti-HdCDT antibodies, may be detected in healthy individuals and in patients with certain disease conditions (e.g. periodontitis), they may not be specific markers for chancroid infection.

Citing Articles

Engineering of Cytolethal Distending Toxin B by Its Reducing Immunogenicity and Maintaining Stability as a New Drug Candidate for Tumor Therapy; an In Silico Study.

Keshtvarz M, Mahboobi M, Kieliszek M, Miecznikowski A, Sedighian H, Rezaei M Toxins (Basel). 2021; 13(11).

PMID: 34822569 PMC: 8624547. DOI: 10.3390/toxins13110785.


Impact of CDT Toxin on Human Diseases.

Fais T, Delmas J, Serres A, Bonnet R, Dalmasso G Toxins (Basel). 2016; 8(7).

PMID: 27429000 PMC: 4963852. DOI: 10.3390/toxins8070220.


Cytolethal distending toxin: a conserved bacterial genotoxin that blocks cell cycle progression, leading to apoptosis of a broad range of mammalian cell lineages.

Jinadasa R, Bloom S, Weiss R, Duhamel G Microbiology (Reading). 2011; 157(Pt 7):1851-1875.

PMID: 21565933 PMC: 3167888. DOI: 10.1099/mic.0.049536-0.


Immune response to cytolethal distending toxin of Aggregatibacter actinomycetemcomitans in periodontitis patients.

Ando E, De-Gennaro L, Faveri M, Feres M, DiRienzo J, Mayer M J Periodontal Res. 2010; 45(4):471-80.

PMID: 20337882 PMC: 3534802. DOI: 10.1111/j.1600-0765.2009.01260.x.


Evaluation of the humoral immune response to the cytolethal distending toxin of Aggregatibacter actinomycetemcomitans Y4 in subjects with localized aggressive periodontitis.

Xynogala I, Volgina A, DiRienzo J, Korostoff J Oral Microbiol Immunol. 2009; 24(2):116-23.

PMID: 19239638 PMC: 2732719. DOI: 10.1111/j.1399-302X.2008.00483.x.